Maharashtra Herald

DelveInsight Business Research LLP

DelveInsight, “Myopia – Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Myopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download the sample page to know more @ Myopia Pipeline 

Myopia Key Highlights 

• The Key Companies working in Myopia include Vyluma, Sydnexis, Ocumension limited, Santen Pharmaceutica, Cloudbreak Therapeutics, and many others.
• The Key Therapies working in Myopia include NVK002, MicroPine, and many others 

Got queries? Click here to learn more about the Myopia Pipeline

Myopia Overview

Myopia, commonly referred to as shortsightedness, is a common cause of visual disability throughout the world. The prevalence of myopia varies by country and by ethnic group, reaching as high as 70-90% in some Asian populations. Myopia occurs if the eyeball is too long or the cornea (the clear front cover of the eye) is too curved. As a result, the light entering the eye isn’t focused correctly, and distant objects look blurred. While the exact cause of myopia is unknown, there is significant evidence that many people inherit myopia, or at least the tendency to develop myopia. 

 Myopia Epidemiological Segmentation 

• Myopia Total Prevalent Cases
• Myopia Severity-specific Prevalence 
• Myopia Age-specific Prevalence 
• Myopia Diagnosed and Treated cases 

Major Players in Myopia

There are approx. 10+ key companies that are developing therapies for Myopia. The companies that have their Myopia drug candidates in the most advanced stage, i.e. Phase III include, Vyluma

Phases

DelveInsight’s Report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono Combination and Mono/Combination.

Table of Contents

•  Key Insights 
•  Report Introduction 
•  Executive Summary of Myopia  
•  Disease Background and Overview
•  Epidemiology and patient population
•  Myopia Emerging Therapies
• Myopia  Market Outlook
•  Market Access and Reimbursement of Therapies
• Appendix
• Myopia  Report Methodology
• DelveInsight Capabilities
•  Disclaimer
•  About DelveInsight

Click here to read more about Myopia pipeline 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services